Abstract Number: 0038 • ACR Convergence 2023
Specific Binding of Uric Acid to NDFIP1 Associates with Hyperuricemia-induced Ferroptosis
Background/Purpose: Hyperuricemia (HU) is reported as a risk factor for gout and associates with diverse diseases, including ulcerative colitis (UC), while its mechanism remains unclear.…Abstract Number: 1110 • ACR Convergence 2023
Pharmacokinetics and Pharmacodynamics of AR882 Following 12-Week Treatment in Patients with Gout
Background/Purpose: In early phase studies AR882 exhibited good dose proportionality, long half-life and dose-dependent serum urate (sUA) lowering effect in a broad range of doses…Abstract Number: 0048 • ACR Convergence 2023
Monosodium Urate Crystals Activate an Immune Tolerance Program That Restrains the Activation of Inflammatory Signaling in Macrophages During Gout Flares
Background/Purpose: Gout is the most frequent form of inflammatory arthritis, with episodes of self-resolving acute inflammation in the joint caused by the deposition of monosodium…Abstract Number: 1111 • ACR Convergence 2023
Urate-Lowering Therapy Is Associated with a Reduced Risk of Arrhythmias: A Systematic Review and Meta-analysis
Background/Purpose: Recent studies have suggested that hyperuricemia is significantly associated with an increased prevalence of atrial and ventricular arrhythmias and urate-lowering therapy (ULT) may provide…Abstract Number: 0234 • ACR Convergence 2023
Identifying Optimal Serum Urate Levels to Reduce Gout Flares in Patients Taking Urate Lowering Therapy: A Post-hoc Cohort Analysis of CARES with Consideration of Drop-out
Background/Purpose: ACR gout treatment guidelines recommend a target serum urate (SU) of < 6 mg/dL and anti-inflammatory flare prophylaxis for at least 3-6 months after…Abstract Number: 1112 • ACR Convergence 2023
AR882, a Potent Uricosuric Agent, Shows Favorable Uric Acid Excretion Profile Following Multiple Doses
Background/Purpose: The uric acid transporter inhibitor (URAT1) is responsible for the reabsorption of filtered uric acid from the renal tubular lumen. Uricosuric agents inhibit URAT1…Abstract Number: 0237 • ACR Convergence 2023
Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network Database
Background/Purpose: Pegloticase, a recombinant pegylated uricase, rapidly reduces serum urate (SU) in patients refractory to/intolerant of oral urate-lowering therapies (ULTs).1,2 However, pegloticase is generally used…Abstract Number: 1145 • ACR Convergence 2023
Human Cardiovascular Disease Model Provides Transcriptomic Evidence of Cardiovascular Risk Associated with Febuxostat
Background/Purpose: Gout is a chronic inflammatory arthritis that is undertreated and managed with the xanthine oxidase inhibitors febuxostat or allopurinol. Despite the United States Food…Abstract Number: 0240 • ACR Convergence 2023
Gout: A Gateway to Chronic Opioid Use?
Background/Purpose: Painful gout flares often lead to healthcare visits which, based on prior reports, results in the use of opioid therapy for flare management, despite…Abstract Number: 1204 • ACR Convergence 2023
Understanding Community Perspectives on Disease Management: A Social Media Analysis of Gout Care Strategies
Background/Purpose: To comprehensively understand the impact of disease management strategies, it is essential to understand the patient perspective. Gout is a chronic inflammatory arthritis characterized…Abstract Number: 0241 • ACR Convergence 2023
Gout Flares During the Initiation and Escalation of Treat-to-Target Urate Lowering Therapy: A Post-hoc Analysis of a Randomized Multicenter Comparative Effectiveness Trial
Background/Purpose: Initiating urate-lowering therapy (ULT) in gout is known to precipitate flares, which can lead to decreased adherence and suboptimal outcomes. Until recently, there has…Abstract Number: 1805 • ACR Convergence 2023
Longitudinal Changes in Serum Urate Associate Minimally with Changes in Daily Alcohol Intake
Background/Purpose: Cross-sectional epidemiologic studies support a direct relationship between alcohol intake and serum urate (SU). These observations are parts of the basis for gout recommendations…Abstract Number: 0244 • ACR Convergence 2023
Efficacy and Safety of AR882, a Selective Uric Acid Transporter 1 (URAT1) Inhibitor, in Gout Patients with Various Baseline Characteristics Following 12-Week Treatment in Patients
Background/Purpose: AR882 is a novel, potent, and selective URAT1inhibitor in development for the treatment of gout and tophaceous gout. AR882-202 was a global, multi-center, randomized,…Abstract Number: 1810 • ACR Convergence 2023
Alcohol Consumption Amount, Type of Beverage, and Gender, All Matters to Serum Uric Acid Levels
Background/Purpose: Alcohol intake has been known to be interrelated with hyperuricemia and gout. However, the results of its influence are conflicting on serum uric acid…Abstract Number: 0245 • ACR Convergence 2023
Impact of Combined Intervention with Clinical Nurse Specialist in the Management of Cardiovascular Risk in Patients with Gout
Background/Purpose: Gout is associated with increased cardiovascular risk (CVR). Traditional CVR factors (CVRF) are frequently present in patients with gout, further worsening the prognosis. Several…
- 1
- 2
- 3
- …
- 6
- Next Page »